<DOC>
	<DOCNO>NCT02468700</DOCNO>
	<brief_summary>To evaluate safety efficacy OTX-DP sustain release drug ( dexamethasone , 0.4mg ) depot place canaliculus eyelid subject exhibit sign symptom dry eye disease .</brief_summary>
	<brief_title>Feasibility Study Evaluating Safety Efficacy OTX-DP ( Sustained Release Dexamethasone , 0.4mg ) Treatment Dry Eye</brief_title>
	<detailed_description>This prospective , multi-center , randomize , parallel-arm , bilateral , double-masked , vehicle control study evaluate safety efficacy OTX-DP compare Placebo Vehicle ( PV ) treatment subject exhibit sign symptom dry eye disease . This serial phase trial . Initially , effect PV establish 6-week Punctum Plug Only Phase . This establish baseline data use analysis Treatment Phase subject randomize study drug ( OTX-DP ) placebo control ( PV ) . Up forty ( 40 ) subject eighty ( 80 ) eye , meet inclusion none exclusion criterion ask participate study .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Has know history ( within past 6 month ) dry eye disease Has correct LogMAR VA ≤ 0.3 ( 20/40 Snellen good ) eye assess Screening Visit Punctum Plug Only Phase : Minimal Cumulative ( five area ) Corneal Fluorescein Staining Score 8 assess Screening Visit eye Treatment Phase : Minimal Cumulative ( five area ) Corneal Fluorescein Staining Score 5 assess Day 1 ( plug insertion ) Treatment Phase eye Has OSDI score ≥18 assess Screening Visit Any history intraocular inflammation presence screen insertion slit lamp examination either eye Active history chronic/recurrent ocular systemic disease uncontrolled likely affect study outcome ( e.g . iritis , uveitis , viral/bacterial keratitis , viral/bacterial/allergic conjunctivitis , Rheumatoid Arthritis , Crohn 's disease , hepatitis C ) Use follow antiinflammatory immunomodulating agent ( e.g . cyclosporine ) ocular systemic duration study . Subjects allow maximum washout period 30 day inform consent PV plug insertion . Washout period medication prior plug insertion follow : Systemic corticosteroid 4 week ( Note : Systemic corticosteroid inhaler nasal spray form exclusionary use stable dose regimen least 30 day prior Visit 1 change medication study period anticipate ) ; Periocular injection corticosteroid solution 3 month ; Corticosteroid intravitreal depot injection either eye 3 month ; Ozurdex either eye 9 month ; Retisert either eye 40 month ; Topical ocular corticosteroid 2 week ; Topical ocular NSAID 7 day ; Topical ocular systemic cyclosporine 1 month Has uncontrolled Glaucoma medication treat glaucoma Has ocular hypertension ( Normalized IOP ≥ 22 mmHg ) , medication treat ocular hypertension history IOP spike either eye Active history chronic recurrent inflammatory eye disease ( e.g . iritis , uveitis ) Active Epiphora Requires use topical ophthalmic solution nonpreserved OTC Tears BID ( maximum frequency ) management dry eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>